The devastating inherited disease cystic fibrosis (CF) is caused by mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) anion channel. The recent approval of the CFTR potentiator drug ivacaftor (Vx-770) for the treatment of CF patients has marked the advent of causative CF therapy. Currently, thousands of patients are being treated with the drug, and its molecular mechanism of action is under intensive investigation. Here we determine the solubility profile and true stimulatory potency of Vx-770 towards wild-type (WT) and mutant human CFTR channels in cell-free patches of membrane. We find that its aqueous solubility is ~200 fold lower (~60 nanomolar), whereas the potency of its stimulatory effect is >100 fold higher, than reported, and is unexpectedly fully reversible. Strong, but greatly delayed, channel activation by picomolar Vx-770 identifies multiple sequential slow steps in the activation pathway. These findings provide solid guidelines for the design of in vitro studies using Vx-770.https://doi.org/10.7554/eLife.46450.001
CFTR belongs to the family of ATP Binding Cassette (ABC) proteins (Riordan et al., 1989), and forms an anion selective channel which is activated by phosphorylation of its cytosolic regulatory (R) domain by cyclic AMP-dependent protein kinase (PKA) (Berger et al., 1991; Tabcharani et al., 1991). In phosphorylated CFTR channels opening and closing (gating) of the anion pore is coupled to conformational changes induced by ATP binding and hydrolysis at two cytosolic nucleotide binding domains (NBDs) (Anderson et al., 1991; Li et al., 1996). CFTR channels are present in the apical membrane of epithelial cells that line the lung, intestine, pancreatic duct, and sweat duct, and the regulated flow of anions, primarily chloride and bicarbonate, through CFTR is indispensable for the salt-water homeostasis of those epithelia. CF, the most common lethal inherited disease among Caucasians, is caused by CFTR mutations which have been classified based on their molecular consequences. Thus, some mutations diminish production (Class I and V), folding/trafficking (Class II), or stability (Class VI) of the CFTR protein, wheres others impair channel gating (Class III), or anion permeation through the open pore (Class IV) (De Boeck and Amaral, 2016). The most common CF mutation, deletion of phenylalanine 508 (ΔF508), is present in ~90% of patients and impairs both channel surface expression (Cheng et al., 1990) and open probability (Miki et al., 2010).
Pharmacotherapy of CF is currently focused on developing compounds that either enhance surface expression (‘correctors’) or stimulate channel gating (‘potentiators’) of mutant CFTR. The potentiator Vx-770 (Van Goor et al., 2009), identified by Vertex Pharmaceuticals using high-throughput screening, has proven successful and was approved by the FDA for the treatment of patients carrying G551D and other gating mutations (Ramsey et al., 2011). This breakthrough has demonstrated the feasibility of efficient causative CF therapy using small-molecule potentiators, at least for this subset of patients (<5% of all CF cases). Moreover, in a recent phase two clinical trial, patients carrying the most common CF mutation ΔF508 also experienced significant clinical improvement from co-administration of Vx-770 with a combination of corrector drugs (Boyle et al., 2014; Wainwright et al., 2015; Davies et al., 2018).
Although treatment with Vx-770 (administered orally, either alone or in combination with corrector drugs) is accepted as the standard of care for the majority of CF patients in the US, many of the basic properties of the drug have remained unexplained or controversial. Thus, CFTR channel stimulation by Vx-770 in cell-free patches is reportedly irreversible (Jih and Hwang, 2013; Lin et al., 2016; Yeh et al., 2015; Yeh et al., 2017; Wang et al., 2014; Wang et al., 2018), maximal stimulation of WT CFTR channels shows large variability (ranging from ~1.1 fold [Cui and McCarty, 2015] to ~3 fold [Wang et al., 2018]), and in some studies its acute application caused (Cholon et al., 2014) – or accentuated (Wang et al., 2014) – CFTR channel inactivation. Vx-770 is routinely used at concentrations up to 10 μM (Cui and McCarty, 2015; Langron et al., 2018; Liu and Dawson, 2014; Van Goor et al., 2009; Van Goor et al., 2014; Yu et al., 2012; Wang et al., 2014; Wang et al., 2018), but data on its aqueous solubility have not yet been published.
We reasoned that some of the reported controversies on Vx-770 effects might be explained by the use of highly supersaturated concentrations of the drug in all published studies, and set out to determine its true solubility profile. Starting from crystalline Vx-770 (Selleck Chemicals), solubilities (S) of the drug in various organic solvents could be readily determined by adding incremental small volumes of solvent until all crystals had been dissolved (Table 1). We found Vx-770 extremely soluble in anhydrous dimethyl sulfoxide (DMSO) (S ~ 0.77 M), and reasonably soluble in 1-octanol (S ~ 3.9 mM) and ethanol (S ~ 3.1 mM). However, even the smallest amounts that we could weigh out (~0.1 mg) failed to dissolve in 1 liter of aqueous saline (pH = 7.1), as evident from clearly visible crystals even after vigorous shaking for 24 hr, forcing us to take a different approach. To generate an aqueous solution exactly saturated with Vx-770, a small aliquot of crystals was added to an aqueous saline (pH = 7.1) and, after vigorous shaking for 24 hr, visible crystals were removed by repeated filtering and microcrystals sedimented by centrifugation (Materials and methods). The resulting supernatant (our ‘1x saturated’ stock solution) was then used both for determination of Vx-770 solubility (Figure 1b–c), and for functional experiments (Figures 2–5). Vx-770 dissolved in 1-octanol at 1–4 μM showed clearly measurable light absorption with a peak at 311 nm (Figure 1b, blue spectra), yielding a calibration line in the micromolar range (Figure 1c, blue dots and fitted straight line). For our 1x saturated aqueous stock solution the absorbance spectrum was flat against the background saline, but when we extracted it with 1-octanol at a volume ratio of 20:1, the extract showed clear absortion (Figure 1b, red spectrum, ‘1st extract’), corresponding to a Vx-770 concentration of ~1.2 μM (Figure 2b). Repeated extraction of the aqueous stock with 1-octanol yielded a flat spectrum (Figure 2a, green spectrum, ‘2nd extract’), confirming that all Vx-770 had been efficiently extracted in the first round. Considering that Vx-770 was concentrated 20-fold during the extraction procedure, we conclude that the true aqueous solubility of Vx-770 at 25°C is only ~60 nM (Saq(25°C, pH = 7.1)=62 ± 2 nM, n = 4), almost 200-fold lower than generally believed, and severalfold lower even than its reported EC50 values for potentiation of various CFTR mutants (160–600 nM) (Van Goor et al., 2014).
Because in all published in vitro studies Vx-770 was applied at concentrations ranging from 100 nM to 10 μM (Cui and McCarty, 2015; Yeh et al., 2015; Yeh et al., 2017; Langron et al., 2018; Liu and Dawson, 2014; Van Goor et al., 2009; Van Goor et al., 2014; Yu et al., 2012; Wang et al., 2014; Wang et al., 2018; DeStefano et al., 2018; Jih and Hwang, 2013; Lin et al., 2016; Kopeikin et al., 2014), our present solubility estimate indicates that Vx-770 effects have so far been characterized only at supersaturated concentrations. We reasoned that this circumstance might explain some of the puzzling features of the drug, such as CFTR channel inactivation observed in some cases (Cholon et al., 2014), as well as apparent irreversibility of drug effects (Jih and Hwang, 2013; Lin et al., 2016; Yeh et al., 2015; Yeh et al., 2017; Wang et al., 2014; Wang et al., 2018). To investigate stability and reversibility of Vx-770 effects in a concentration range that can be achieved in the human body during oral drug administration, we tested the effects of our 1x saturated Vx-770 solution and its dilutions in inside-out patches excised from Xenopus laevis oocytes expressing WT or mutant human CFTR channels.
Indeed, in inside-out patches (Figure 2a), application of our 1x saturated Vx-770 solution (red bar) to prephosphorylated WT CFTR channels opened by 2 mM ATP (gray bar) caused rapid robust (~4 fold) current stimulation which lasted as long as the drug was applied. However, upon drug removal the current readily declined back to its pre-drug value (time constant τ ~2 min, Figure 2a, red fit line), demonstrating full reversibility of Vx-770 effects. In single-channel recordings (Figure 2b), even a 20-fold dilution of our 1x saturated Vx-770 stock stimulated open probability of WT CFTR to a comparable level, by ~4 fold (Figure 2c, left). Stimulation of open probability was due to acceleration of channel opening and slowing of channel closure (Figure 2b, top and center trace; Figure 2c, red vs. dark gray bars), consistent with previous studies in which the drug had been applied at supersaturating concentrations (Kopeikin et al., 2014; Jih and Hwang, 2013). However, in contrast to those earlier studies, the observed effects on channel gating were fully reversible following washout of the drug (Figure 2b, bottom trace; Figure 2c, light gray bars).
To estimate the true stimulatory potency of the drug, a series of dilutions of our 1x saturated Vx-770 stock was first tested on WT CFTR channels (Figure 3a, red bars). We observed robust stimulation of WT CFTR currents by even a 100-fold dilution of our 1x saturated Vx-770 stock (Figure 3a, second trace from left), suggesting a subnanomolar apparent affinity for the drug. Indeed, a dose response curve (Figure 3c, red symbols), obtained by assuming [Vx-770]=62 nM in our 1x saturated stock (cf., Table 1), yielded a K0.5 of 0.47 ± 0.12 nM (Figure 3c, red fit line). As a control, a dose response relationship obtained by exposure of WT CFTR channels to known concentrations of Vx-770 (Figure 3b, brown bars), obtained by sequential dilutions of a commercially available 10 mM DMSO-based Vx-770 stock (Selleck Chemicals), yielded a K0.5 for current stimulation of 0.49 ± 0.15 nM (Figure 3c, brown symbols and fit line), confirming our estimate of Vx-770 aqueous solubility. Thus, the apparent K0.5 of Vx-770 for stimulation of WT CFTR is ~600 fold lower than previously reported (~300 nM [Van Goor et al., 2014; Langron et al., 2018]).
When tested on patches containing G551D (Figure 3d) or ΔF508 (Figure 3e) CFTR channels, robust current stimulation was also observed already at subnanomolar concentrations. For both mutants maximal current stimulation was 11–12-fold with a K0.5 of ~1.5 nM (Figure 3f, blue and green symbols and fit lines), and was fully reversible with a time constant of ~2 min (Figure 3d–e, fitted lines). Thus, the true potency of Vx-770 for G551D CFTR is ~200 fold higher, and for ΔF508 CFTR 20–300-fold higher, than previously reported (Van Goor et al., 2009; Yu et al., 2012; Van Goor et al., 2014; Langron et al., 2017).
The kinetics of current deactivation following Vx-770 wash-off was well fitted assuming a single rate-limiting step (Figure 4a, green single-exponential fit lines and time constants τ). In contrast, the activation time course upon drug exposure was clearly sigmoidal, suggesting the presence of multiple sequential slow steps in the activation pathway. Indeed, at least three sequential concentration-dependent slow steps were required to obtain an adequate fit (Figure 4a, blue fit lines). In particular, at subnanomolar/low nanomolar aqueous drug concentrations current stimulation started off with a marked delay of up to ~1 min (Figure 4a, gray trace), consistent with slow drug accumulation in the membrane being required for CFTR potentiation (Jih and Hwang, 2013). As expected, deactivation rate (1/τoff) was independent of drug concentration (Figure 4c), whereas the overall rate of activation (1/τon*, see Materials and methods) became faster at higher concentrations (Figure 4b). At a single-channel level both application and removal of low concentrations of Vx-770 (Figure 4d, top, red bar) caused abrupt changes in channel open probability, but with a marked delay (Figure 4d, stability plot, red vs. gray bars; bottom, expanded current segments).
We next attempted to interpret the observed complex kinetics of the drug effects in terms of various molecular models (Figure 5a–d), by performing global fits of each model (Figure 5f, colored lines) to the ensemble of four experimentally observed current time courses: activation and deactivation upon addition and removal of 0.01x saturated (Figure 5f, gray trace) and 1x saturated (Figure 5f, black trace) Vx-770. To reduce the number of free parameters in the considered models, the equilibrium ratio of membrane-dissolved and aqueous concentrations of Vx-770 (i.e., the ratio kin/kout, Figure 5a–d) was fixed to its measured octanol/water distribution coefficient (Doct/wat(pH=7.1)=62580, logD = 4.8, cf., Table 1), a well-established approximator of membrane/water distribution for a large number of diverse drugs with logD values ranging between 1 and 5.5 (Gobas et al., 1988).
One slow step involved in both activation and deactivation might be drug equilibration between the membrane and the aqueous phase (described by rate constants kin and kout), and/or binding/unbinding between membrane-dissolved drug and the channel protein (described by rate constants kon' and koff). However, a simple two-step mechanism (Scheme 1, Figure 5a) was clearly insufficient to account for the marked delay in channel activation observed at low drug concentrations (Figure 5f, green fit lines).
Given that in inside-out patch-clamp experiments Vx-770 enters the membrane only from the cytosolic side during drug application, whereas it can leave the membrane on both sides following drug wash-off, one additional slow step specific to the activation process could be slow flipping of the drug into the outer membrane leaflet, if the binding site on the CFTR protein resided on the extracellular half of its transmembrane region (Scheme 2, Figure 5b, flip-flop rates are assumed symmetrical (kflip)). However, whereas such a two-compartment membrane model provides sufficient flexibility for perfectly fitting any individual, highly sigmoidal, on- time course (Figure 5—figure supplement 1, solid pink fit line), or even for reasonably describing an entire on-off current time course for any given drug concentration (Figure 5—figure supplement 1, solid red and blue fit lines), the ensemble fit of the entire data set by Scheme 2 (Figure 5f, pink fit lines) was barely improved relative to the fit by Scheme 1 (Figure 5f, green fit lines), despite the introduction of an additional free parameter (kflip).
An alternative mechanism that could explain delayed activation by the drug is the presence of multiple drug binding sites, all of which must be occupied to switch the channel to a high open probability state. Of note, a recent study suggested two potential binding sites for Vx-770 in the transmembrane domains of CFTR (Yeh et al., 2019). We therefore evaluated a simplistic model which postulates independent drug binding to two sites, with identical affinities, but a substantial change in open probability (from Po;bas to Po;max) only for diliganded channels (Scheme 3, Figure 5c). Interestingly, although it contains no additional free parameters relative to Scheme 1, Scheme 3 provided a dramatically improved ensemble fit, yielding a single set of rate constants (Figure 5e, left) that can reasonably account for the current activation and deactivation time courses observed in response to addition and removal of Vx-770, over a 100-fold concentration range (Figure 5f, blue fit lines).
Finally, assuming a two-compartment membrane and two drug-binding sites, both accessible from the outer leaflet (Scheme 4, Figure 5d), afforded a further small improvement (Figure 5f, red fit lines) relative to Scheme 3, albeit at the expense of an extra free parameter (Figure 5e, right).
The pH of our standard bath solution (7.1) resembles intracellular pH, but extracellular pH in the human body is typically higher (~7.4). This transmembrane pH gradient might influence the distribution of Vx-770 in the body, as the drug contains two potentially deprotonatable groups (Figure 1a, red arrows), and the negative charge acquired upon deprotonation is expected to greatly enhance its aqueous solubility. Because the computationally (Chemaxon) predicted strongest acidic pKa value varies between 6.57 and 8.66, depending on the method of prediction, we measured Vx-770 solubility in our standard bath solution after adjusting its pH to 7.4 (see Materials and methods). From three independent measurements we obtained an estimate of Saq(25°C, pH = 7.4) = 50 ± 1 nM (mean ± S.E.M.), which is not larger than that obtained for pH = 7.1, the small difference likely reflecting experimental limitations. This finding suggests that the strongest acidic pKa value of the drug is substantially higher than 7.4, and so the uncharged, fully protonated form remains the dominant microspecies in the entire physiological pH range. The corollary is that the aqueous solubility of the drug is similar in the cytosol and the extracellular space.
As a further parameter of clinical interest, we also determined the aqueous solubility of Vx-770 at body temperature (pH = 7.1). Consistent with reports for other hydrophobic drugs (Baena et al., 2004; Garzón and Martínez, 2004; Mota et al., 2009), Vx-770 aqueous solubility at 37°C was ~2 fold higher compared to that at 25°C, three independent measurements yielding an estimate of Saq(37°C, pH = 7.1) = 138 ± 1 nM (mean ± S.E.M.). The standard enthalpy of solution, estimated from the solubilities at 37°C vs. 25°C, is ΔHosol = +51.2 kJ/mol, and the standard free energy of solution at 25°C is ΔGosol = +41.1 kJ/mol (Materials and methods). Thus, the thermodynamic explanation for the extremely low aqueous solubility of Vx-770 is that the entropy increase (TΔSosol = +10.1 kJ/mol at 25°C) associated with the solution process is too small to compensate for the large increase in enthalpy, likely caused by the disruption of hydrogen bonds between water molecules.
The discovery of the CFTR potentiator Vx-770 has caused a major change in the therapy of CF patients, allowing to address for the first time the root cause of the disease. To date, thousands of patients are taking the drug on a daily basis, which warrants that studying its mechanisms will remain in the center of research efforts for years to come. As for all drugs approved for clinical use, extensive clinical studies have established its pharmacokinetic profile and safety features, and quantified its clinical effects. On the other hand, many of its basic physicochemical properties, as well as its precise molecular mechanism of action, remain to be established. Vx-770 shows good oral bioavailability, and peak plasma concentrations of ~4 μM, and >10 μM, respectively, have been measured in patients receiving twice daily 150 mg (therapeutic) or 450 mg (supratherapeutic) doses (FDA report by Vertex Pharmaceuticals Incorporated, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203188Orig1s000OtherRedt.pdf). In the plasma, most of the drug is bound to plasma proteins, which are important for its pharmacokinetics, as they tremendously increase the drug transport capacity of the blood and therefore oral bioavailability, and act as a drug buffer system that replenishes the free drug pool during the time course of its elimination from the body. On the other hand, cell membranes are at equilibrium with free dissolved Vx-770, not with the protein-bound drug. Therefore, in a living organism the target cell membranes will accumulate Vx-770 only to an extent that is at equilibrium with free dissolved Vx-770 (in the extracellular fluid and/or in the cytosol). In the present study, we have established an upper limit for the latter parameter, which thus determines the maximal possible drug concentration achievable in target cell membranes. We have further shown that Vx-770 solubility is independent of pH in the physiological pH range, which implicitly indicates that its smallest acidic pKa value is far higher than 7.4, and that the dominant microspecies is therefore the fully protonated uncharged form. Consequently, the distribution of the drug between the cytosol and extracellular space is unaffected by the transmembrane pH gradient and the membrane potential.
Because in all published in vitro studies Vx-770 was applied at concentrations ranging from 100 nM to 10 μM (Cui and McCarty, 2015; Yeh et al., 2015; Yeh et al., 2017; Langron et al., 2018; Liu and Dawson, 2014; Van Goor et al., 2009; Van Goor et al., 2014; Yu et al., 2012; Wang et al., 2014; Wang et al., 2018; DeStefano et al., 2018; Jih and Hwang, 2013; Lin et al., 2016; Kopeikin et al., 2014), our present solubility estimate (50–62 nM at 25°C, 138 nM at 37°C) indicates that Vx-770 effects have so far been characterized only at highly (up to ~200 fold) supersaturated concentrations, that also exceed (by up to ~100 fold) the highest free drug concentrations that can be ever attained at 37°C, that is in the human body using oral drug administration. This circumstance readily explains some of the reported puzzling features of the drug. For instance, when superfusing a patch with a supersaturated aqueous solution of Vx-770, the drug will accumulate at supersatured concentrations even in the membrane, likely resulting in the formation, and time-dependent growth, of crystalline precipitates within the bilayer. Such precipitates might have contributed to CFTR channel inactivation observed in some studies (Cholon et al., 2014). Moreover, following removal of Vx-770 from the aqueous perfusate, the membrane-dissolved drug pool might be replenished from such intra-membrane crystalline precipitates as long as the crystals last (which will depend on the degree of supersaturation of the applied aqueous test solution, and on exposure time), explaining the reported irreversibility of drug effects (Jih and Hwang, 2013; Lin et al., 2016; Yeh et al., 2015; Yeh et al., 2017; Wang et al., 2014; Wang et al., 2018). Indeed, we show here that the potentiating effect of Vx-770 on CFTR is fully reversible (Figures 2–3), as long as supersaturating drug concentrations are avoided.
Based on our data (Figure 3c,f), the apparent affinity of Vx-770 for WT CFTR is 600-fold, for G551D CFTR ~200 fold, and for ΔF508 CFTR 20–300-fold higher than previously reported. One likely explanation for the discrepancy between previous estimates of Vx-770 potencies and those obtained here is the use of static recording chambers in the previous studies as opposed to the continuous superfusion employed here. The octanol/water distribution coefficient of Vx-770 is ~60000 (cf., Table 1). Thus, if cellular membranes constitute as little as ~0.17% of the total assay volume, then ~99% of the drug will accumulate in those membranes and its free aqueous concentration will remain only ~1% of the total. Furthermore, when applied at supersaturated concentrations, large fractions of the drug will precipitate onto the walls of the recording chamber.
Precise molecular interpretation of the complex kinetic steps involved in drug-activation (Figure 4a) will clearly require much further work, including definitive localization of the drug binding site(s). However, a simple kinetic model which postulates two independent and similar-affinity binding sites, with potentiation requiring simultaneous binding of two drug molecules (Scheme 3, Figure 5c), afforded a remarkably good description of current activation/deactivation time courses over a broad range of applied drug concentrations (Figure 5f, blue fit lines). The reasonable fit of an ensemble of four highly non-linear curves by a single set of only four free parameters (kout, kon', koff, and Po;max/Po;bas; with kin constrained to kin = kout⋅Doct/wat(pH=7.1)) strongly argues in favor of this model. Recently, in silico docking to high-resolution CFTR structures of the potentiator GLPG-1837, a drug known to compete with Vx-770 for CFTR activation (Yeh et al., 2017), identified potential drug binding sites in CFTR's transmembrane domains (Yeh et al., 2019). Interestingly, mutations introduced into either of two putative sites strongly impaired potentiation by both GLPG-1837 and Vx-770 (Yeh et al., 2019). However, because dose response curves for GLPG-1837 activation are fitted with Hill coefficients close to unity, the authors were uncertain how to interpret those findings. They suggested that either both sites are true drug binding sites, or only one site is a true binding site, while mutations at the other site allosterically affect the structure of the true site. Of note, Scheme 3 predicts an apparent Hill slope of only ~1.17 (see Materials and methods) which is consistent with the values obtained both for GLPG-1837 by Yeh and colleagues, and for Vx-770 in the present study (Figure 3). We therefore consider Scheme 3 the best current working model for describing the molecular mechanism of CFTR potentiation by Vx-770. Average rate constants obtained from ensemble fits to three pairs of current traces, such as those in Figure 5f, are summarized in Table 2 (left).
Considering that measured diffusion coefficients of small molecules within a lipid bilayer fall in the range of 10−8 to 10−7 cm2/s (Ladha et al., 1996; Macháň and Hof, 2010), the apparent second-order on-rates (kon') of Vx-770 obtained from the fits to Scheme 3 are several orders of magnitude slower than expected for diffusion-limited binding of membrane-dissolved drug molecules to the CFTR protein. One possible explanation for this slow apparent on-rate could be that the drug remains associated with the polar surface of the bilayer, consistent with the hydrogen bonding capability of its five polar groups (Figure 1a). In that case, if the drug binding sites on the CFTR protein are located in the outer leaflet of the membrane, drug binding could be rate limited by slow flipping of the drug from the inner to the outer leaflet. Such a scenario could be consistent with the location of the two binding sites proposed by Yeh and colleagues, which are closer to the extracellular than to the intracellular membrane surface (Yeh et al., 2019). However, despite the introduction of an additional free parameter (kflip), a two-compartment membrane model (Scheme 4, Figure 5d) only marginally improved the fits (Figure 5f, red fit lines). Thus, unless molecular dynamics simulations provide further support for such a model, we do not consider Scheme 4 (Figure 5d, Table 2, right) a substantially better working model compared to Scheme 3. An alternative possible explanation for the drug's slow apparent on-rate could be diffusion-limited loose binding followed by a slower induced fit conformational change.
Two common mechanistic conclusions suggested by the Scheme-3 and Scheme-4 fits are that (i) two drug molecules need to bind to the channel protein to achieve potentiation, and that (ii) the slow channel deactivation time course following drug removal reflects the slow dissociation rate of the bound drug from the protein (koff), rather than slow washout of unbound drug molecules from the membrane (kout).
In conclusion, we have established the basic physicochemical properties of Vx-770, including its solubility profile and the thermodynamic parameters of the aqueous solution process. We have further determined its true potency towards WT, G551D, and ΔF508 CFTR, which is orders of magnitude higher than previously believed. Finally, we have identified a kinetic model which is suitable to describe its molecular mechanism. Our findings provide a solid framework to guide extensive current research efforts aimed at studying Vx-770 effects in vitro. A clinically relevant aspect of our findings is that half-maximal CFTR potentiation is achieved already by an ~100 fold dilution of a saturated Vx-770 solution. Thus, it might be worth testing whether drug doses lower than the currently approved dosage regimes are equally beneficial to CF patients, as this could reduce treatment costs that are currently ~300000 USD/patient/year.
Crystalline Vx-770 (purity 99.58% by HPLC) was purchased from Selleck Chemicals (Houston, TX, USA). Solubilities (S) at 25°C in anhydrous dimethyl sulfoxide (DMSO) (S ~ 0.77 M), 1-octanol (S ~ 3.9 mM), ethanol (S ~ 3.1 mM), octane (S ~ 2.6 mM), and pentane (S ~ 18 μM) were determined by weighing out a small amount (1–2 mg) of crystals on an analytical balance (Kern ABJ), and adding incremental small volumes of solvent, followed by mixing, until all crystals had been dissolved. However, even the smallest amount of Vx-770 that we could weigh out (~0.1 mg, obtained by manually dividing an ~0.5 mg aliqout into five comparable heaps under a stereomicroscope) failed to dissolve in 1 liter of water, as evident from clearly visible crystals even after vigorous shaking (200 RPM, New Brunswick Excella E24) for 24 hr at 25°C.
To obtain an aqueous solution (pH = 7.1) exactly saturated with Vx-770 (our ‘1x saturated’ stock), a small aliquot of Vx-770 crystals (~0.1 mg) was added to 250 ml of our standard bath solution (in mM: 134 NMDG-Cl, 2 MgCl2, 5 HEPES, 0.5 EGTA, pH = 7.1 with NMDG), and the solution was shaken for 24 hr at 25°C at 200 RPM (New Brunswick Excella E24). Remaining, clearly visible, macrocrystals were removed by filtering the solution twice through an 0.22 μm pore size filter (Millipore Durapore Steritop + Stericup, Merck KGaA, Darmstadt, Germany). To sediment invisible microcrystals, the filtrate was centrifuged at 7200 RCF for 1 hr in 50 ml conical tubes, and the supernatant carefully removed, leaving the last ~1 ml behind. The resulting cleared filtrate was stored and used as a stock solution for all subsequent studies.
The concentration of Vx-770 in the 1x saturated stock was determined by spectrophotometry (NanoPhotometer P300, Implen GmbH). Vx-770 dissolved in 1-octanol shows strong absorption with a peak at 311 nm. To obtain a calibration curve, Vx-770 (from a commercial 10 mM stock dissolved in DMSO, purchased from Selleck Chemicals) was diluted into 1-octanol (saturated with water) to final concentrations of 1, 2, 4, 8, and 16 μM. Absorption spectra were measured in a 1 ml quartz cuvette against 1-octanol (saturated with water) as a blank (Figure 1b, blue spectra). Peak absorption at 311 nm was linear with Vx-770 concentration across the entire range (the 0–4 μM range is shown in Figure 1c, blue dots). To extract Vx-770 from the 1x saturated aqueous stock, two 15 ml conical tubes, each containing 14 ml of the 1x aqueous stock plus 0.7 ml 1-octanol, were vortexed for 1 min, and then centrifuged at 7200 RCF for 30 min. Approximately 2 × 0.6 ml of the 1-octanol phase was recovered, pooled, and its absorption spectrum measured in a 1 ml quartz cuvette against 1-octanol (saturated with water) as a blank (Figure 1b, red spectrum). To extract the remaining aqueous phase for a second time, the remnants of the 1-octanol phase were carefully discarded from both conical tubes, and 12.5 ml of the remaining aqueous phase (removed by inserting the pipette tip well below the surface) was transferred into two clean conical tubes. The extraction was then repeated using 2 × 0.625 ml 1-octanol, from which 2x ~ 0.5 ml was recovered, pooled, and assayed for optical density (Figure 1b, green spectrum).
Aqueous solubility at pH = 7.4 (25°C) was measured as described above for pH = 7.1, but starting from a standard bath solution with pH adjusted to 7.4 using NMDG. The spectrophotometric calibration curve was obtained in this case using 1, 2, 4, 8, and 16 μM Vx-770 dissolved in 1-octanol (saturated with the pH = 7.4 bath solution). The obtained calibration curve was identical to that shown in Figure 1b–c (i.e., Vx-770 fluorescence was insensitive to whether it was dissolved in 1-octanol saturated with water (as in Figure 1), or with saline buffered to either pH = 7.1, 7.3, or 7.4).
To determine aqueous solubility at 37°C (pH = 7.1), an aliquot of standard bath solution was heated to 37°C in a water bath. Because the pKa of HEPES is temperature dependent, heating to 37°C caused a decrease in pH by 0.17 units. The pH of the solution was therefore readjusted to 7.1 at 37°C using NMDG. To obtain a 1x saturated solution at 37°C, overnight shaking with Vx-770 crystals, subsequent 2x filtering, and centrifugation were all perfomed at 37°C. To measure Vx-770 concentration in the 1x saturated stock solution, 0.7 ml 1-octanol was added to 14 ml aliquots of the stock at 37°C, the tubes were vortexed for 1 min, and the subsequent steps of the 1-octanol extraction procedure, as well as the spectrophotometric determination, were performed at room temperature, as described above.
The standard enthalpy of solution was calculated as ΔHosol = ((RT1T2)/(T2−T1))⋅ln(S(T2)/S(T1)), where R = 8.31 Jmol−1K−1, T1 = 298 K (25°C), T2 = 310 K (37°C), and S(T1) and S(T2) are the measured aqueous solubilities of Vx-770 at the respective temperatures (pH = 7.1). The standard free energy of solution at T = 298 K (25°C) was calculated as ΔGosol = −RT⋅ln(S(T)).
The G551D and ΔF508 mutations were introduced into pGEMHE-CFTR using the QuikChange Kit (Agilent, Santa Clara, CA, USA), and confirmed by automated sequencing; cDNA was purified (HiSpeed Plasmid Midi Kit, Qiagen), transcribed in vitro (mMessage T7 Kit, ThermoFisher Scientific, Waltham, MA USA) and cRNA stored at −80°C.
Oocytes were extracted from anaesthethized adult female Xenopus laevis (RRID: NXR_0.0080) following Institutional Animal Care Committee guidelines, isolated using collagenase treatment (Gibco, Collagenase type II), injected with 0.1–10 ng cRNA in a fixed 50 nl volume, and stored at 18°C in a modified frog Ringer's solution (in mM: 82 NaCl, 2 KCl, 1 MgCl2, and 5 HEPES, pH 7.5 with NaOH) supplemented with 1.8 mM CaCl2 and 50 μg/ml gentamycin. Current recordings were obtained 1–3 days after injection.
Patch pipette solution contained (in mM): 136 NMDG-Cl, 2 MgCl2, 5 HEPES, pH = 7.4 with NMDG. Bath solution contained (in mM): 134 NMDG-Cl, 2 MgCl2, 5 HEPES, 0.5 EGTA, pH = 7.1 with NMDG. MgATP (2 mM) was added from a 400 mM aqueous stock solution (pH = 7.1 with NMDG). Before each experiment 300 nM catalytic subunit of PKA (Sigma-Aldrich Kft., Budapest, Hungary) was applied for ~1 min to phosphorylate CFTR channels. Vx-770 (Selleck Chemicals) was diluted into the bath solution either from a ‘1x saturated’ aqueous stock solution (see above, concentration ~62 nM), or from a commercially obtained 10 mM stock dissolved in DMSO (Selleck Chemicals). Following patch excision the patch pipette was moved into a flow chamber, and recordings were done under continuous superfusion of the cytosolic patch surface. Solution compositions were exchanged using computer-driven electronic valves (solution exchange time constant <50 ms). After each recording day perfusion tubings were extensively washed with distilled water. Although supersaturated solutions of Vx-770 were not employed here, any perfusion tubing that had ever been in contact with a given concentration of Vx-770 was subsequently used only for solutions that contained the same, or higher, concentrations of the drug. After every 5–6 experimental days the entire perfusion system was replaced. Currents were recorded at 25°C, at a membrane potential of −40 mV, digitized at 10 kHz, Gaussian-filtered at 2 kHz, and recorded to disk (Axopatch 200B, Digidata 1322A, Pclamp9 (Molecular Devices, RRID: SCR_011323)). For display purposes, currents are shown filtered at 10 Hz and sampled at 20 Hz, and expanded single-channel traces (Figure 2b, Figure 4d) are shown filtered at 50 Hz and sampled at 250 Hz.
Vx-770 was applied after currents elicited by 2 mM ATP had stabilized. To allow for full development of its potentiator effect, Vx-770 was superfused until the current reached steady state which, for low nanomolar Vx-770, required up to 5–6 min. After full stimulation, Vx-770 was washed off for at least 5 min to allow the current to decline to a post-drug steady state. Fractional current stimulation by Vx-770 (I/Icontrol) was calculated as the mean steady current in the presence of the drug, divided by the average of the pre- and post-drug mean steady currents. Dose response curves (Figure 3c,f) were least-squares fitted to the modified Hill equation I/Icontrol=(K0.5n+(Imax/Icontrol)[Vx-770]n)/(K0.5n+[Vx-770]n), with Imax/Icontrol, K0.5, and n as free parameters.
To obtain apparent deactivation rates, current decay time courses following Vx-770 removal were fitted by single exponentials using least squares, and deactivation rates defined as the inverse of the decay time constant (1/τoff; Figure 4c). To obtain apparent activation rates, current activation time courses upon Vx-770 addition were fitted to an empirical three-step kinetic scheme S1→S2→S3→S4. Compound states S1-S4 in this scheme are not interpreted as channel conformational states, but rather as states of the entire system (aqueous solution +patch membrane leaflets + channels), and could reflect various stages of drug distribution among those compartments. The open probability (Po) of CFTR channels in compound states S1, S2, and S3 was fixed to the Po observed for single WT CFTR channels under control conditions (~0.16; Figure 2c), whereas the Po for CFTR channels in compound state S4, and transition rates k12, k23, and k34, were left free (Figure 4a). (Whereas this simple irreversible scheme is clearly unsuitable to explain reversibility of drug effects, and does not address the mechanism of the drug, it provided sufficient flexibility for a perfect fit of individual activation time courses.) Apparent activation time constants (τon*) were defined as T1/2/ln2, where T1/2 is the time required for the current to cross the midpoint between its pre-activated and fully activated amplitudes. Apparent activation rates were defined as 1/τon* (Figure 4b).
Segments of current recording originating from 1 to 7 active channels were digitally filtered at 50 Hz, and idealized by half-amplitude threshold crossing. Steady-state open probabilities in 2 mM ATP, before or during application of Vx-770 or after its removal (Figure 2c), were calculated from the events lists as the time-average of the fraction of open channels. A closed-open-blocked (C-O-B) kinetic scheme, which separates brief (~10 ms) flickery closures (to state B) from long (~1 s) interburst closures (to state C), was fitted by maximum likelihood to the set of dwell-time histograms for all conductance levels, to obtain microscopic transition rates rCO, rOC, rOB, and rBO, while accounting for a fixed dead time of 6 ms (Csanády, 2000). The software is freely available upon request. Mean burst (τb) and interburst (τib) durations were calculated as τb=(1/rOC)(1 + rOB/rBO) and τib=1/rCO, and channel opening and closing rates (Figure 2c) defined as 1/τib and 1/τb, respectively. The stability plot in Figure 4d was obtained by calculating open probability over sequential 46 s time windows.
The dynamic equations that describe the kinetic models depicted in Figure 5 are as follows:
dx1(t)/dt = kin⋅Vc – 2⋅kout⋅x1(t) – kon'⋅x1(t)⋅x2(t) + koff⋅(Ct–x2(t))
dx2(t)/dt = – kon'⋅x1(t)⋅x2(t) + koff⋅(Ct–x2(t))
where x1(t) is the concentration of free Vx-770 in the membrane, x2(t) is the concentration of unliganded drug binding sites (CFTR channels) in the membrane, Ct is the total concentration of drug binding sites (CFTR channels) in the membrane, and Vc is the concentration of Vx-770 in the cytosol.
dx1(t)/dt = kin⋅Vc – (kout +kflip)⋅x1(t) + kflip⋅x2(t)
dx2(t)/dt = kflip⋅x1(t) – (kout +kflip)⋅x2(t) – kon'⋅x2(t)⋅x3(t) + koff⋅(Ct–x3(t))
dx3(t)/dt = – kon'⋅x2(t)⋅x3(t) + koff⋅(Ct–x3(t))
where x1(t) is the concentration of Vx-770 in the inner membrane leaflet, x2(t) is the concentration of free Vx-770 in the outer membrane leaflet, x3(t) is the concentration of unliganded drug binding sites (CFTR channels) in the outer membrane leaflet, Ct is the total concentration of drug binding sites (CFTR channels) in the outer membrane leaflet, and Vc is the concentration of Vx-770 in the cytosol.
dx1(t)/dt = kin⋅Vc – 2⋅kout⋅x1(t) – kon'⋅(2⋅x2(t)+x3(t))⋅x1(t) + koff⋅(2⋅(Ct–x2(t)–x3(t))+x3(t))
dx2(t)/dt = – 2⋅kon'⋅x1(t)⋅x2(t) + koff⋅x3(t)
dx3(t)/dt = 2⋅kon'⋅x1(t)⋅x2(t) + 2⋅koff⋅(Ct–x2(t)–x3(t)) – (koff +kon'⋅x1(t))⋅x3(t)
where x1(t) is the concentration of free Vx-770 in the membrane, x2(t) is the concentration of unliganded CFTR channels in the membrane, x3(t) is the concentration of monoliganded CFTR channels in the membrane, Ct is the total concentration of CFTR channels in the membrane, and Vc is the concentration of Vx-770 in the cytosol.
dx1(t)/dt = kin⋅Vc – (kout +kflip)⋅x1(t) + kflip⋅x2(t)
dx2(t)/dt = kflip⋅x1(t) – (kout +kflip)⋅x2(t) – kon'⋅(2⋅x3(t)+x4(t))⋅x2(t) + koff⋅(2⋅(Ct–x3(t)–x4(t))+x4(t))
dx3(t)/dt = – 2⋅kon'⋅x2(t)⋅x3(t) + koff⋅x4(t)
dx4(t)/dt = 2⋅kon'⋅x2(t)⋅x3(t) + 2⋅koff⋅(Ct–x3(t)–x4(t)) – (koff +kon'⋅x2(t))⋅x4(t)
where x1(t) is the concentration of Vx-770 in the inner membrane leaflet, x2(t) is the concentration of free Vx-770 in the outer membrane leaflet, x3(t) is the concentration of unliganded CFTR channels in the outer membrane leaflet, x4(t) is the concentration of monoliganded CFTR channels in the outer membrane leaflet, Ct is the total concentration of CFTR channels in the outer membrane leaflet, and Vc is the concentration of Vx-770 in the cytosol.
To calculate the value of Ct, the total number of channels in the patch (N) was estimated by assuming Po;bas=0.16 for prephosphorylated channels in ATP (cf., Figure 2c). For Schemes 1 and 3 the volume of the membrane patch was taken as 10−16 liter (assuming a macroscopic patch surface area of ~4 μm2 increased by ~5 fold at a microscopic level due to the presence of microvilli (Dascal, 1987), and a membrane thickness of ~5 nm), and for Schemes 2 and 4 the volume of the outer membrane leaflet was taken as 5⋅10−17 liter. Ct was then calculated as N/NA divided by the relevant volume (NA, Avogadro's number). (In control trials in which up to 5-fold larger/smaller fixed membrane volumes were used, the fits showed little sensitivity to the choice of membrane volume, apart from appropriate rescaling of the obtained values for kon' and kflip.)
For the ensemble fitting, all experimental current traces were normalized to their steady-state values observed prior to exposure to Vx-770. Predicted normalized on- and off- current time courses for each model were calculated from the above dynamic equations by solving for the time-dependent evolution of the vector x, using a modified Euler's method (Press, 1992). For the on- time courses the initial values for all xi were set to zero, for the off- time courses the final x vector of the preceding on- time course served as the initial vector while Vc was set to zero. The predicted time course of the normalized current trace was then obtained as x2(t)/Ct + (1–x2(t)/Ct)⋅(Po;max/Po;bas) (Scheme 1), x3(t)/Ct + (1–x3(t)/Ct)⋅(Po;max/Po;bas) (Scheme 2), (x2(t)+x3(t))/Ct + (1–(x2(t)+x3(t))/Ct)⋅(Po;max/Po;bas) (Scheme 3), and (x3(t)+x4(t))/Ct + (1–(x3(t)+x4(t))/Ct)⋅(Po;max/Po;bas) (Scheme 4), respectively. The sets of predicted normalized on-off time courses were fitted to the sets of normalized experimental current traces by simple least squares, using a downhill simplex method for optimization (Press, 1992).
Under the conditions used here, that is upon prolonged exposure of the cytosolic face of the patch to a constant concentration of Vx-770, with no Vx-770 present on the extracellular side, all four kinetic models shown in Figure 5 predict relaxation of the system to a steady state. At steady state there is a constant outward directed transmembrane flux of Vx-770, while its concentration remains constant within the membrane (or membrane leaflets), and close to zero in the extracellular (pipette) solution. (The volume of the pipette solution, on the order of 10−5 l, can be considered infinitely large relative to the volume of the patch membrane). For Schemes 1 and 3, the steady-state membrane concentration of the drug is Vm;∞=Vc⋅kin/(2⋅kout). For Schemes 2 and 4, the steady-state drug concentrations in the cytosolic and external membrane leaflets (Vmc;∞, Vme;∞), respectively, are given by Vmc;∞=Vc⋅(kin/kout)⋅(kout +kflip)/(kout +2⋅kflip) and Vme;∞=Vc⋅(kin/kout)⋅kflip/(kout +2⋅kflip).
Once the drug concentrations in the various compartments have stabilized, the channel pool approaches an equilibrium distribution between its available (unliganded, ligandbound, and, for Schemes 3 and 4, diliganded) forms. The concentration-dependence of steady-state current activation reflects the concentration-dependence of the fractional occupancy of the monoliganded state (Y1) for Schemes 1 and 2, but of the diliganded state (Y2) for Schemes 3 and 4. The latter are given by Y1 = V∞/(Kd;mem +V∞) and Y2 = (V∞/(Kd;mem +V∞))2, respectively, where Kd;mem = koff/kon', and V∞=Vm;∞ for Schemes 1 and 3, but V∞=Vme;∞ for Schemes 2 and 4. The midpoints of these predicted concentration response curves (K0.5;mem), that is the drug concentrations in the target compartment (membrane or external membrane leaflet) that cause half-maximal stimulation, are obtained as K0.5;mem = Kd;mem for Schemes 1 and 2, but K0.5;mem = (1+√2)⋅Kd;mem for Schemes 3 and 4. When plotted using a logarithmic abscissa, the midpoint slope of the dose response curve for Schemes 3 and 4 corresponds to that of a Hill function with Hill coefficint nH = 2⋅(2–√2). The apparent drug affinities (K0.5;aq), that is the drug concentrations in the cytosolic solution that cause half-maximal stimulation, are obtained as K0.5;aq = K0.5;mem/(kin/(2⋅kout)) for Schemes 1 and 3, but K0.5;aq = K0.5;mem/((kin/kout)⋅kflip/(kout +2⋅kflip)) for Schemes 2 and 4.
Data are presented as mean ± S.E.M from 3 to 13 independent measurements, as indicated in the figure legends. Statistical significance was quantified using Student's two-tailed t test, differences are reported as not significant for p>0.05, and significant for p<0.05* or p<0.01**.
All data generated or analyzed during this study are included in the manuscript or can be visualized in the figures.
Temperature-dependence of the solubility of some acetanilide derivatives in several organic and aqueous solventsPhysics and Chemistry of Liquids 42:603–613.https://doi.org/10.1080/00319100412331284413
Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channelJournal of Clinical Investigation 88:1422–1431.https://doi.org/10.1172/JCI115450
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosisScience Translational Medicine 6:246ra96.https://doi.org/10.1126/scitranslmed.3008680
Murine and human CFTR exhibit different sensitivities to CFTR potentiatorsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology 309:L687–L699.https://doi.org/10.1152/ajplung.00181.2015
VX-659-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del allelesNew England Journal of Medicine 379:1599–1611.https://doi.org/10.1056/NEJMoa1807119
Physiological and pharmacological characterization of the N1303K mutant CFTRJournal of Cystic Fibrosis 17:573–581.https://doi.org/10.1016/j.jcf.2018.05.011
Temperature dependence of solubility for ibuprofen in some organic and aqueous solventsJournal of Solution Chemistry 33:1379–1395.https://doi.org/10.1007/s10953-004-1051-2
Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channelsJournal of Cystic Fibrosis 13:508–514.https://doi.org/10.1016/j.jcf.2014.04.003
Lateral diffusion in planar lipid bilayers: a fluorescence recovery after photobleaching investigation of its modulation by lipid composition, cholesterol, or alamethicin content and divalent cationsBiophysical Journal 71:1364–1373.https://doi.org/10.1016/S0006-3495(96)79339-6
Improved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compoundsBritish Journal of Pharmacology 174:525–539.https://doi.org/10.1111/bph.13715
Potentiation of the cystic fibrosis transmembrane conductance regulator by VX-770 involves stabilization of the pre-hydrolytic, O1 stateBritish Journal of Pharmacology 175:3990–4002.https://doi.org/10.1111/bph.14475
ATPase activity of the cystic fibrosis transmembrane conductance regulatorJournal of Biological Chemistry 271:28463–28468.https://doi.org/10.1074/jbc.271.45.28463
Lipid diffusion in planar membranes investigated by fluorescence correlation spectroscopyBiochimica Et Biophysica Acta (BBA) - Biomembranes 1798:1377–1391.https://doi.org/10.1016/j.bbamem.2010.02.014
Potentiation of disease-associated cystic fibrosis transmembrane conductance regulator mutants by hydrolyzable ATP analogsJournal of Biological Chemistry 285:19967–19975.https://doi.org/10.1074/jbc.M109.092684
Temperature and solvent effects in the solubility of some pharmaceutical compounds: measurements and modelingEuropean Journal of Pharmaceutical Sciences 37:499–507.https://doi.org/10.1016/j.ejps.2009.04.009
BookNumerical Recipes in C. the Art of Scientific Computing (Second Edition)Vetterling T, Teukolsky S. A, Flannery B. P, editors. Cambridge University Press.
A CFTR potentiator in patients with cystic fibrosis and the G551D mutationThe New England Journal of Medicine 365:1663–1672.https://doi.org/10.1056/NEJMoa1105185
Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTRNew England Journal of Medicine 373:220–231.https://doi.org/10.1056/NEJMoa1409547
Potentiation of the cystic fibrosis transmembrane conductance regulator cl- channel by ivacaftor is temperature independentAmerican Journal of Physiology-Lung Cellular and Molecular Physiology 315:L846–L857.https://doi.org/10.1152/ajplung.00235.2018
Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770The Journal of General Physiology.https://doi.org/10.1085/jgp.201912360
Ivacaftor potentiation of multiple CFTR channels with gating mutationsJournal of Cystic Fibrosis 11:237–245.https://doi.org/10.1016/j.jcf.2011.12.005
Leon D IslasReviewing Editor; Universidad Nacional Autónoma de México, Mexico
Richard AldrichSenior Editor; The University of Texas at Austin, United States
Leon D IslasReviewer; Universidad Nacional Autónoma de México, Mexico
Sidney SimonReviewer; Duke University, United States
In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.
[Editors’ note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.]
Thank you for submitting your work entitled "Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations" for consideration by eLife. Your article has been reviewed by three peer reviewers, including Leon D Islas as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Sidney Simon (Reviewer #3).
Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in eLife.
While the reviewers agree that the data presented in the manuscript is sound and represents an important technical development in understanding the action of ivacaftor on CFTR, they also think that the paper did not provide any insight into the molecular interaction of the drug with the channel and the determinants of solubility in biological tissues. The reviewers point out that this diminishes the relevance and interest of the paper to a broader readership.
The CFTR Cl- ion channel is responsible for adequate mucus secretion in respiratory epithelia. Multiple mutations are associated with CFTR dysfunction and consequent induction of cystic fibrosis (CF), which can be lethal. One of the few treatments approved for CF is the drug Vx-770, which has been shown to be effective in potentiating CFTR mutants characterized by a low open probability, a gating defect.
In this paper by Csanády and Töröcsik present data that resolve a standing controversy in the CFTR and Vx-770 literature and which could also have an impact in the clinical application of this drug to CF patients.
The experiments included in this manuscript show that Vx-770 has an extremely low solubility in water. As a consequence of this, the dose utilized in diverse laboratories is likely extremely high and mostly undetermined, accounting for the different values of EC50 reported. More interestingly, Vx-770 effects are reportedly irreversible. This manuscript presents a determination of the solubility of Vx-770 in several solvents, including water, and shows that when the correct activating doses (below nM concentrations) are applied, the drug effects are perfectly reversible.
The experiments are of high quality and represent a solid foundation to start to understand the biophysics and molecular basis of the gating effects of this drug.
In addition, this is an important contribution that might have clinical relevance, as it will help understand the pharmacokinetics of Vx-770.
I have a suggestion regarding the use of the multiple-step model employed to explain the delay in activation time course when Vx-770 is applied. The suggested model is an irreversible model, which may appear as a contradiction with the finding that the drug effects are indeed reversible. Also, it should be clear what state occupancy is being compared with the current time course. And finally it should be clearly stated that this is not a scheme that explain gating, that is, states S1 to S4 are not to be interpreted as channel conformational states.
In this study the authors determine the solubility profile and stimulatory potency of Vx-770 (ivacaftor), a CFTR potentiator drug in clinical use to treat people with cystic fibrosis, towards wild-type and mutant human CFTR channels using the patch-clamp technique with excised inside-out membrane patches. They find that its solubility in aqueous saline (pH=7.1) is ~200-fold lower (~60 nanomolar), whereas the potency of its stimulatory effect is >100-fold higher, than previously reported, and is fully reversible. They find evidence that several slow steps are involved in the activation pathway. The experiments are generally well done and of high quality. The manuscript is well written. However, significance is reduced because no new insight is gained how Vx-770 interacts with CFTR to activate channel activity. Usually a methodological progress is presented in the context of describing an important new insight that could be obtained because of the method. In addition, because solubility in biological fluids at physiological pH and body temperature is not studied, the results appear only relevant to a small group of readers who perform CFTR patch clamp electrophysiology with excised membrane patches.
In addition, I have the following comments:
In subsection “CFTR channel stimulation by Vx-770 is fully reversible”: the authors state "up to ~200-fold higher than those that can be ever attained in the human body using oral drug administration." This statement appears not justified by the data. The authors do not study solubility of Vx-770 in biological fluids and tissues. For instance, protein present in a biological intra- or extracellular fluid may increase solubility substantially. In this context it is also not clear to me why the authors do not test solubility at 37°C and pH values that resemble intra- or extracellular pH.
Figure 2C: A one-tailed Student t-test appears not appropriate. First, since CFTR channel inactivation by Vx-770 has been described among the effects of Vx-770 in the literature (see Introduction section final paragraph) the statistical test should be two-tailed. Second, repeated measurement ANOVA should be considered since technically there are two interventions with the same channel.
In this paper the WT and two mutants of the CTFR channel are investigated in inside out patches in the absence and presence of continually perfused Vx-770, a clinically relevant drug used in CF patients. In my opinion the most important finding of this work is that they found is that, in contrast to previous studies that found Vx-770 to be irreversible, they found that by using lower concentrations that it is completely reversible. They measured its oil (octanol etc.)/water (saline) partition coefficient although I think it would have been more useful to measure the membrane (GUV's) +/- cholesterol/saline partition coefficient given they were testing the drug in frog oocytes. Moreover, since they wrote "the basic properties of the drug remain unknown or controversial", I think a description of the drug, its shape (planar), purity (important as K1/2 = 0.47 nM) and its pKa values in salt and low dielectric media (if known, and if not discuss) would be useful to the reader. Also, I would like to know (if known) where on the membrane or channel is it binding and if its action a consequence of membrane deformation and/or to a binding site on CTFR that has not been alluded to. In their methods they vortexed the Xstals but I wonder if they ever sonicated and/or heated them to get them into solution.
[Editors’ note: what now follows is the decision letter after the authors’ article was reconsidered after an appeal.]
Thank you for submitting your article "Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations" for consideration by eLife. Your article has been reviewed by Leon Islas as Reviewing Editor and Reviewer #1, and the evaluation has been overseen Richard Aldrich as the Senior Editor.
The editors have discussed the appeal with one another and are happy to consider a revised version of your manuscript.
The paper by Csanády and Töröcsik describes in detail the solubility of the clinically important drug ivacaftor, an activator of CFTR channels. This is an appeal of a previous decision and the author's proposed changes for improvement are reasonable and will improve the paper. Our suggestion is that you make the changes that are proposed in your appeal letter, especially place more emphasis on the clinical and physiological relevance of the findings. Pay attention to the suggestion of measuring solubility at 37°C and make a point of clarifying the applicability of the results to the context of biological fluids. A discussion of the implication of the results for the pharmacokinetics of ivacaftor can also help to further the case for the clinical relevance of the present findings.https://doi.org/10.7554/eLife.46450.012
[Editors’ note: the author responses to the first round of peer review follow.]
I kindly ask for the reevaluation of the reasons that have led to the rejection of our manuscript, and for a potential reconsideration of the editorial decision. The Reviewers all agreed that the results support the conclusions. The rejection was based on two issues: (1) a lack of insight into the molecular interaction of the drug with the channel, and (2) a lack of information on its solubility in biological tissues. I have serious objections against both of these major criticisms, as discussed in detail below.
1) "significance is reduced because no new insight is gained how Vx-770 interacts with CFTR to activate channel activity. Usually a methodological progress is presented in the context of describing an important new insight that could be obtained because of the method." (Reviewer 2)
As to the question of significance, I had sent a presubmission inquiry to Senior Editor Richard Aldrich, describing him the main findings of this study, and explicitly pointing out that no biological mechanisms are addressed. In his response, Dr. Aldrich judged the findings of sufficient interest, and encouraged submission to eLife. It comes therefore as a surprise that the findings are judged insignificant at the present stage. I do agree that in general determination of solubility and potency of a drug is in itself not a major advance. But there are not many drugs that make it to the clinics, and ivacaftor is one of them. The fact that ~100000 CF patients are taking the drug on a daily basis warrants that studying its mechanisms will remain in the center of research efforts for years to come. On the other hand, despite a very large number (>500) of studies published on the drug since its discovery, both its binding site on the protein and its mechanism remain elusive, in large part due to inadequately designed experiments in which highly supersaturated solutions were used. Therefore, I do think that in the present case the simple establishment of the drug's true solubility profile, true potency, and concentration dependence of its apparent on- and off-rates, is a major breakthrough which will put all published studies into a new perspective, and allow all future studies to be planned adequately.
As to the second point, reviewers 2 and 3 seem to have misunderstood the relevance of a saturated vs. supersaturated solution, and they have confounded the relevance of drug-protein binding with that of true solubility. In truth − except for a potential effect on solubility of elevating temperature to 37oC (which we could verify) − all our results apply to the biological fluids and cell membranes of a living organism, as discussed below.
2.1) "solubility in biological fluids at physiological pH and body temperature is not studied" and"the authors state "up to ~200-fold higher than those that can be ever attained in the human body using oral drug administration." This statement appears not justified by the data. The authors do not study solubility of Vx-770 in biological fluids and tissues. For instance, protein present in a biological intra- or extracellular fluid may increase solubility substantially." (Reviewer 2)
Of course, it is well known that Vx-770 binds to plasma proteins, and total plasma concentrations in patients following drug administration have been measured and documented by the FDA: peak total plasma concentrations may reach values up to 10 μM. However, cell membranes are at equilibrium with FREE dissolved Vx-770, not with the protein-bound drug. Therefore, in a living organism the target cell membranes will accumulate Vx-770 only to an extent that is at equilibrium with FREE dissolved Vx-770 (in the extracellular fluid and/or in the cytosol). Thus, although drug binding proteins are important for pharmacokinetics (they increase the drug transport capacity of the blood and therefore oral bioavailability, and act as a drug buffer system that replenishes the free drug pool during the time course of its elimination from the body), for the effective drug concentration in the target cell membrane the only relevant parameter is FREE dissolved Vx-770 − for which we have established an upper limit here.
2.2) "In this context it is also not clear to me why the authors do not test solubility at 37°C and pH values that resemble intra- or extracellular pH." (Reviewer 2)
The composition of the aqueous saline in which Vx-770 solubility was determined resembled that of an intracellular fluid with respect to ionic strength, osmolarity, as well as pH (7.1). We did not test solubility at 37oC, but this could be very easily added. Of note, although solubility at 37oC is clearly of academic interest, we believe that solubility at 25oC is practically more relevant: solubility has to be known under the conditions that are used in experiments aimed at understanding the mechanisms of the drug. The majority of such experiments have been conducted at room temperature.
2.3) "I am sure Vx-770 will bind to various biological structures and proteins when it is in the body so I doubt it at supersaturated concentrations in the fluid phase." (Reviewer 3)
This is a misunderstanding. We did not claim that supersaturated concentrations are reached in the body. Quite on the contrary, we claim that in the body FREE drug concentrations will never become higher than saturated.
2.4) "Is there any evidence that Vx-770 will form crystalline precipitates in the bilayer?" (Reviewer 3)
This is a thermodynamic necessity. When a saturated aqueous solution is at equilibrium with a membrane, the membrane also has to be saturated. Similarly, when a membrane is exposed to a supersaturated solution (that is, a solution which is kept supersaturated by continuous superfusion), the membrane will also become supersaturated. Thus, over time crystals will have to form. Indirect experimental evidence comes from our demonstration that Vx-770 effects are fully reversible when supersaturating concentrations are avoided, whereas they are reportedly irreversible when supersaturated solutions are used.
2.5) "by definition a solution is saturated when it is in equilibrium with its bulk phase (i.e. Xstals)- it is not necessarily supersaturated then." (Reviewer 3)
We agree. This is exactly how we generated our 1x saturated stock: by equilibrating the solution with crystals, followed by removal of undissolved crystals. In contrast, in previous studies supersaturated solutions were obtained by diluting Vx-770 from a DMSO-based stock into an aqueous buffer. Because Vx-770 is 10-million times more soluble in DMSO compared to water, it is easy to generate supersaturated aqueous solutions using the latter approach.
3) The remaining comments are all issues that could be easily amended as follows:
3.1) "I have a suggestion regarding the use of the multiple-step model employed to explain the delay in activation time course when Vx-770 is applied. The suggested model is an irreversible model, which may appear as a contradiction with the finding that the drug effects are indeed reversible. Also, it should be clear what state occupancy is being compared with the current time course. And finally it should be clearly stated that this is not a scheme that explain gating, that is, states S1 to S4 are not to be interpreted as channel conformational states." (Reviewer 1)
The reviewer is absolutely right that the modeled states are not interpreted as channel conformational states, but rather as states of the entire system (aqueous solution + patch membrane leaflets + channels), and likely reflect various stages of drug distribution between those compartments. It is also true that in its present (irreversible) form the fitted scheme seems to contradict the demonstrated reversibility of the drug effects, and so allowing reversibility for all three steps would seem logical. However, in the absence of more specific structural information, we feel that postulation of any specific mechanistic model would be highly speculative. We therefore simply aimed to find the mathematical function with the smallest number of free parameters suitable to describe the on- time courses, and used the fitted curves only to obtain the apparent on- time constant (τ*). All this could be of course stated and explained much more clearly in Materials and methods.
3.2) "Figure 2C: A one-tailed Student t-test appears not appropriate. First, since CFTR channel inactivation by Vx-770 has been described among the effects of Vx-770 in the literature (see Introduction section final paragraph) the statistical test should be two-tailed. Second, repeated measurement ANOVA should be considered since technically there are two interventions with the same channel." (Reviewer 2)
This can be easily amended.
3.3) "They measured its oil (octanol etc.)/water (saline) partition coefficient although I think it would have been more useful to measure the membrane (GUV's) +/- cholesterol/saline partition coefficient given they were testing the drug in frog oocytes." (Reviewer 3)
The primary purpose of this study was to determine the aqueous solubility of the drug. Solubilities in ethanol or DMSO were added for practical reasons, since those solvents are used by researchers to generate stock solutions of the drug. Solubility in octanol, and the octanol:water partition coefficient, were determined for three reasons. First, the octanol:water distribution coefficient is a very good predictor of a drug's overall membrane solubility, and is one of the key parameters used in the pharmaceutical industry to compare drugs. Second, octanol is immiscible with water, and can therefore be conveniently used to extract the drug from the aqueous phase. Third, Vx-770 dissolved in octanol is a well defined, homogeneous, single-phase system (a true solution) in which the drug concentration can be readily measured using spectrophotometry. The latter two properties were exploited to determine the aqueous solubility of the drug. In contrast, GUV's (i) represent a poorly defined system (with properties highly dependent on lipid composition), (ii) form a colloidal suspension in water rather than a homogeneous system, and (iii) determination of drug solubility in GUV's would be technically challenging.
3.4) "a description of the drug, its shape (planar), purity (important as K1/2 = 0.47 nM) and its pKa values in salt and low dielectric media (if known, and if not discuss) would be useful to the reader." (Reviewer 3)
Formula and shape can be added to Figure 1. Purity (99.58% by HPLC by manufacturer's certificate of analysis) can be added to Materials and methods. Obtaining pKa values experimentally would be challenging given low nanomolar aqueous solubility. Computational predictions yield pKa values that scatter broadly, depending on the algorithm used (e.g., Chemaxon Chemicalize, Marvin). This information can be added.
3.5) "Also, I would like to know (if known) where on the membrane or channel is it binding and if its action a consequence of membrane deformation and/or to a binding site on CTFR that has not been alluded to." (Reviewer 3)
Neither the binding site of the drug on the channel protein, nor its mechanism of action is currently known.
3.6) "In their methods they vortexed the Xstals but I wonder if they ever sonicated and/or heated them to get them into solution." (Reviewer 3)
Sonication is primarily useful for the dispersion of particles in a solvent to generate a colloid (dispersion, suspension or emulsion), such as a preparation of micelles from amphipathic detergent molecules, or unilamellar vesicles from membrane lipids. It is true that sonication can also speed up dissolution of small molecules, however, it can easily result in the generation of supersaturated solutions. Therefore, for the determination of true solubility sonication is better avoided. Our approach of vigourous shaking of drug crystals in small volumes (250 ml) of buffer for 24 hours seems a safer approach for reaching thermodynamic equilibrium. Of note, in four independent experiments we obtained identical final aqueous drug concentrations (62 ± 2 nM) following removal of undissolved crystals (by filtering + centrifugation), although the total amount of added drug was not identical, as the crystals were not weighed out on a balance. This indicates that in all four cases saturation was achieved.
Heating is clearly irrelevant for the determination of drug solubility at 25oC. For academic reasons, solubility at 37oC could be measured as an additional piece of information. See also response to comment 2.2 above.
[Editors’ note: the author responses to the re-review follow.]
The paper by Csanády and Töröcsik describes in detail the solubility of the clinically important drug ivacaftor, an activator of CFTR channels. This is an appeal of a previous decision and the author's proposed changes for improvement are reasonable and will improve the paper.
We thank the editors for giving us a chance to address the concerns raised in the original reviews. We have extensively revised the manuscript along three major lines:
i) We have measured pH-dependence (in the physiological pH range), as well as temperature dependence of aqueous solubility of Vx-770, and calculated thermodynamic parameters of the solution process. We find that solubility is not increased when pH is elevated from 7.1 (intracellular pH) to 7.4 (extracellular pH). This implies that the smallest acidic pKa value of the drug is substantially higher than 7.4. Therefore, in physiological fluids, the major microspecies of the drug is the fully protonated uncharged form. Thus, the distribution of the drug between the extra- and intracellular space is not influenced by the transmembrane pH gradient or the membrane potential (subsection “pH- and temperature dependence of Vx-770 solubility” first paragaph). We further find an ~2-fold higher aqueous solubility of the drug at 37oC relative to 25oC, which is consistent with reported temperature dependences of solubilities of other highly hydrophobic drugs, and offers a thermodynamic explanation for the low solubility of Vx-770 (subsection “pH- and temperature dependence of Vx-770 solubility” second paragraph).
ii) While this paper was under review, a study, presented at the 2019 European Cystic Fibrosis Society Basic Science Conference, identified two potential binding sites of Vx-770 on the CFTR protein using in silico docking combined with site-directed mutagenesis. These findings, published in the mean time in the Journal of General Physiology (Yeh et al., 2019), have prompted us to attempt proposing and testing mechanistic kinetic models to explain the complex time courses of channel activation/deactivation that we had observed in response to addition/removal of the drug. Our modeling is indeed consistent with the presence of two independent binding sites for Vx-770 on the CFTR protein, and suggests that channel potentiation requires simultaneous binding of two drug molecules. These extensive modeling results are summarized in a new section of Results, two new figures (Figure 5 and Figure 5—figure supplement 1), and a new Table (Table 2).
iii) To clarify misunderstandings, and to better explain the physiological relevance of our findings, we now provide a more elaborate discussion of our findings. Due to the expansion of both data and discussion, the original "Results and Discussion" section has now been separated into "Results" and "Discussion".
These major additions have significantly broadened the scope of our study, which we now hope will be found suitable for publication.
Our suggestion is that you make the changes that are proposed in their appeal letter, especially in response to the minor issues raised in the previous review and that you place more emphasis on the clinical and physiological relevance of the findings.
We now discuss physiological implications at several places. In particular, we discuss the relevances (i) of protein-bound vs. free Vx-770 to drug transport vs. drug accumulation in target cell membranes (Discussion paragraph one), (ii) of aqueous solubility as an upper limit of free drug concentration in the body (Discussion paragraph one), (iii) of drug deprotonation to the distribution of the drug between the extra- and intracellular space (subsection “pH- and temperature dependence of Vx-770 solubility” paragraph one; Discussion first paragraph), (iv) of two-orders-of-magnitude higher (compared to reported values) apparent drug affinities to clinical dosage regimes (Discussion section final paragraph).
Pay attention to the suggestion of measuring solubility at 37°C and make a point of clarifying the applicability of the results to the context of biological fluids.
We have measured solubility at 37oC (subsection “pH- and temperature dependence of Vx-770 solubility” second paragraph), and have analyzed the thermodynamic implications of the data (second paragraph). Applicability of the results to biological fluids is clarified in the Discussion (first paragraph).
A discussion of the implication of the results for the pharmacokinetics of ivacaftor can also help to further the case for the clinical relevance of the present findings.
As mentioned above, we now discuss the relevance of protein-bound Vx-770 to drug pharmacokinetics, and of free Vx-770 to drug accumulation in target cell membranes (Discussion first paragraph). We also discuss that the measured aqueous solubility provides an upper limit of free drug concentration in the body. Finally, we discuss how deprotonation might affect the distribution of a drug between the extra- and intracellular space. We show that Vx-770 remains fully protonated (uncharged) and that, therefore, the transmembrane pH gradient and membrane potential do not affect its distribution (subsection “pH- and temperature dependence of Vx-770 solubility”; Discussion first paragraph).https://doi.org/10.7554/eLife.46450.013
- László Csanády
- László Csanády
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Supported by MTA Lendület grant LP2017-14/2017 and Cystic Fibrosis Foundation Research Grant CSANAD17G0.
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of Semmelweis University (last approved 06-30-2016, expiration 06-30-2021).
- Richard Aldrich, The University of Texas at Austin, United States
- Leon D Islas, Universidad Nacional Autónoma de México, Mexico
- Leon D Islas, Universidad Nacional Autónoma de México, Mexico
- Sidney Simon, Duke University, United States
© 2019, Csanády and Töröcsik
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Electron bifurcation is a fundamental energy conservation mechanism in nature in which two electrons from an intermediate-potential electron donor are split so that one is sent along a high-potential pathway to a high-potential acceptor and the other is sent along a low-potential pathway to a low-potential acceptor. This process allows endergonic reactions to be driven by exergonic ones and is an alternative, less recognized, mechanism of energy coupling to the well-known chemiosmotic principle. The electron-bifurcating [FeFe] hydrogenase from Thermotoga maritima (HydABC) requires both NADH and ferredoxin to reduce protons generating hydrogen. The mechanism of electron bifurcation in HydABC remains enigmatic in spite of intense research efforts over the last few years. Structural information may provide the basis for a better understanding of spectroscopic and functional information. Here, we present a 2.3 Å electron cryo-microscopy structure of HydABC. The structure shows a heterododecamer composed of two independent ‘halves’ each made of two strongly interacting HydABC heterotrimers connected via a [4Fe–4S] cluster. A central electron transfer pathway connects the active sites for NADH oxidation and for proton reduction. We identified two conformations of a flexible iron–sulfur cluster domain: a ‘closed bridge’ and an ‘open bridge’ conformation, where a Zn2+ site may act as a ‘hinge’ allowing domain movement. Based on these structural revelations, we propose a possible mechanism of electron bifurcation in HydABC where the flavin mononucleotide serves a dual role as both the electron bifurcation center and as the NAD+ reduction/NADH oxidation site.
Topoisomerase V is a unique topoisomerase that combines DNA repair and topoisomerase activities. The enzyme has an unusual arrangement, with a small topoisomerase domain followed by 12 tandem (HhH)2 domains, which include 3 AP lyase repair domains. The uncommon architecture of this enzyme bears no resemblance to any other known topoisomerase. Here, we present structures of topoisomerase V in complex with DNA. The structures show that the (HhH)2 domains wrap around the DNA and in this manner appear to act as a processivity factor. There is a conformational change in the protein to expose the topoisomerase active site. The DNA bends sharply to enter the active site, which melts the DNA and probably facilitates relaxation. The structures show a DNA-binding mode not observed before and provide information on the way this atypical topoisomerase relaxes DNA. In common with type IB enzymes, topoisomerase V relaxes DNA using a controlled rotation mechanism, but the structures show that topoisomerase V accomplishes this in different manner. Overall, the structures firmly establish that type IC topoisomerases form a distinct type of topoisomerases, with no similarities to other types at the sequence, structural, or mechanistic level. They represent a completely different solution to DNA relaxation.